Mechanism of Action of Bria-IMT™ and Bria-OTS™

The mechanism of action of Bria-IMT™/Bria-OTS™ is currently under investigation.

We believe that Bria-IMT™/Bria-OTS™, activates the patient’s immune system to recognize tumor cells and destroy them. We hypothesize that Bria-IMT™/Bria-OTS™,  exerts its action via changing the tumor’s antigen-presentation system {i.e. the system that presents antigen material on the surface of the tumor cell – to be recognized by the T cells of the immune system as either self (i.e., safe) or foreign (i.e., to be destroyed)}. Specifically, Bria-IMT™/Bria-OTS™,  may stimulate the dendritic cells, a key component of the antigen-presenting system, to display certain immunogenic (i.e., immune response-generating) protein fragments to T cells, which activates the T Cells to destroy the tumor cells either directly, or by inducing a humoral (antibody-generating) immune response.  In addition, we also have shown that Bria-IMT™ is capable of directly stimulating cancer-fighting T cells.  This further boosts the immune response against the tumor cells and enhances anti-cancer activity.

Our preliminary analyses have shown several up-regulated genes in Bria-IMT™ that encode proteins known to be immunogenic (i.e. immune response-generating), suggesting that Bria-IMT™ can stimulate the immune system against the cancer cells.

Bria-IMT™ is a human breast cancer cell line which expresses Her2/neu (a protein well known for its overexpression in breast cancer but also associated other epithelial malignancies including ovarian, pancreatic, colon, bladder and prostate cancers). Bria-IMT™ has been engineered to produce and secrete granulocyte-macrophage-colony stimulating factor (GM-CSF), a protein that promotes dendritic cell function, a key component of the immune system, and hence activates the immune system.

BriaCell Presentation at the 2020 San Antonio Breast Cancer Symposium®– December 9-11, 2020 BriaCell’s Presentation at 2020 AACR Meeting – June 22, 2020 BriaCell’s Presentation at 2020 American Society of Clinical Oncology (ASCO) Meeting – May 29, 2020 BriaCell Presentation at 2019 San Antonio Breast Cancer Symposium®– December 12, 2019 BriaCell Therapeutics Corp.’s Poster Presentation at AACR Annual Meeting – April 2019 BriaCell™ Therapeutics Corp.’s Poster Presentation at SABCS@– Dec 2018 Publication – Frontiers in Immunology – May 2018 Poster Presentation - AACR - April 18, 2016

Bria-IMT™ & Bria-OTS™
Potential Mechanisms of Specific Immune Activation in Advanced Breast Cancer

  1. Bria-IMT/OTS™ produces breast cancer antigens (proteins made by breast cancer cells)
  2. Bria-IMT/OTS™ secretes GM-CSF which further promotes dendritic cell-based antigen presentation (boosts the response)
  3. Breast cancer antigens are taken up by dendritic cells and “presented” to CD4+ and CD8+ T cells implicated in tumor destruction.
  4. Bria-IMT/OTS™ directly stimulates cancer fighting CD4+ and CD8+ T cells (further boosts the response)
  5. Bria-IMT/OTS™ efficacy depends on HLA matching of Bria-IMT/OTS™ and the patient